Cancer R&D Deal: GSK is paying up to $1.3B to Hutchmed for HMPL-A830, an EGFR-targeted KRAS-blocking antibody-targeted therapeutic conjugate aimed at colorectal, pancreatic and lung cancers, with clinical work expected to start this year outside mainland China/HK/Macau/Taiwan. Cardiovascular Drug Access: Milestone Pharmaceuticals says China’s NMPA approved etripamil nasal spray for adult PSVT, the first approval outside the U.S., with Everest Medicines holding an exclusive Greater China license that includes Taiwan. Alzheimer’s Treatment Update: China approved a subcutaneous lecanemab (LEQEMBI) initiation option for early Alzheimer’s disease, expanding the route and use-case for the therapy. Pediatric Surgery Collaboration: Doctors at Mongolia’s NCMCH, with France and Taiwan specialists, completed surgeries on 30 children for congenital heart defects, cleft lip/palate and craniofacial anomalies. Smart Aging-Care Tech: Inkwater’s Docter platform is pushing an integrated smart aging-care system connecting home monitoring, senior residences and hospital care. Taiwan Health Tech in Action: Taiwan and South Pacific allies signed a statement to deepen cooperation, including a Belau National Hospital AI system and hydrogen/solar energy projects. Health-Adjacent Policy: Taiwan’s NHI “health coin” program is described as open to eligible people including foreign residents. Clinical Case Spotlight: A rare post-surgery bowel complication in Taiwan left a patient unable to keep food down for months, highlighting how “wide-open” bowel can still fail to function.